| Entry |
|
|---|
| Name |
Abicipar pegol (USAN/INN);
Abicipar pegol (genetical recombination) (JAN) |
|---|
| Formula |
C628H985N175O203S2 (C2H4O)n
|
|---|
| Sequence |
GSDLDKKLLE AARAGQDDEV RILMANGADV NARDSTGWTP LHLAAPWGHP EIVEVLLKNG
ADVNAADFQG WTPLHLAAAV GHLEIVEVLL KYGADVNAQD KFGKTAFDIS IDNGNEDLAE
ILQKAAGGGS GGGSC |
|---|
| Type |
Peptide |
|---|
| Remark |
|
|---|
| Efficacy |
Macular degeneration therapeutic agent |
|---|
| Comment |
Treatment of neovascular wet age-related macular degeneration and diabetic macular edema
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01L OCULAR VASCULAR DISORDER AGENTS
S01LA Antineovascularisation agents
S01LA07 Abicipar pegol
D11517 Abicipar pegol (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Growth factors (RTK-binding)
VEGFA
D11517 Abicipar pegol (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
